Rank: Advanced Member Groups: Administration
, Member
Joined: 1/15/2009
Posts: 2,276
Location: Cambridge , MA
|
Dan,
Thanks for bringing the database discrepancy to light so we could work on fixing this. If you go to the Research Pipeline entry now, you should be able to see an entry for our study. Unfortunately, however, this particular entry is incomplete as it was a very early study at TDF and not all the data from these early studies are in our current database. There was no indication of efficacy associated with this drug, however.
As this was an early study and the dosing was via IntraCerebral Ventricular with a pump, there were also some technical issues with the study that lowers interpretability. A number of the pumps failed, for example, and our preferred dosing today might be Intrathecal (IT; directly to the lumbar spine region as opposed to the brain). The existing data from the 2005 publication suggesting efficacy in the ALS mouse would probably not be statistically significant. However, there is some interesting biology that might support the NMDA receptor (a target for Memantine) as a target in ALS. Therefore, Memantine is on a list of drugs that we are in the process of re-evaluating for study though probably not in a full-powered studied (with corresponding high use of resources) – but perhaps via our newer LDA studies.
John McCarty, PhD
Treatment Investigator,
ALS Therapy Development Foundation
John McCarty, PhD
Director of Therapeutic Investigation
ALS Therapy Development Institute
|